<DOC>
	<DOCNO>NCT01793948</DOCNO>
	<brief_summary>This randomize clinical trial study metformin hydrochloride overweight obese patient elevate risk breast cancer . Metformin hydrochloride may decrease expression early tumor maker breast tissue patient increase risk breast cancer</brief_summary>
	<brief_title>Metformin Hydrochloride v . Placebo Overweight Obese Patients Elevated Risk Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine change signal pathway profile breast tissue use reverse phase proteomics tissue biopsy overweight obese woman elevate risk breast cancer treat metformin ( metformin hydrochloride ) ( 850mg orally twice day ) 12 cycle . SECONDARY OBJECTIVES : I . To determine effect metformin breast tissue density overweight obese woman elevate risk breast cancer use qualitative mammographic fat density criterion . II . To determine effect metformin insulin axis serum overweight obese woman elevate risk breast cancer treat metformin ( 850mg orally twice day ) 12 cycle . III . To determine toxicity associate metformin . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive metformin hydrochloride mouth daily day 1-30 course 1 twice daily day 1-30 thereafter . Treatment repeat every 30 day 12 course absence disease progression unacceptable toxicity . ARM II : Patients receive placebo mouth daily day 1-30 course 1 twice daily day 1-30 thereafter . Treatment repeat every 30 day 12 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients must postmenopausal woman ; postmenopausal woman define : ( 1 ) &gt; = 50 year age menstruate precede 12 month castrate folliclestimulating hormone level ( &gt; 40 IU/L ) , ( 2 ) undergone bilateral oophorectomy Patients must elevate risk breast cancer base strong family history history breast biopsy document atypical hyperplasia anytime past ; study strong family history define : 1 firstdegree ( parent , offspring , sibling ) relative = &lt; 50 year old diagnose breast cancer , &gt; = 2 firstdegree relative age diagnose breast cancer , &gt; = 2 seconddegree ( aunt , uncle , grandparent , grandchild , niece , nephew , halfsiblings ) maternal paternal relative diagnose breast cancer least 1 diagnosed = &lt; 50 year age Patients must body mass index ( BMI ) &gt; = 25.0 calculate formula : weight pound / height square x 703 = BMI ; BMI : 18.524.9 consider normal ; 25.029.9 consider overweight ; 30.0+ regard obese Patients must willing complete bilateral mammogram baseline repeat exam 12 cycle protocol therapy ; patient mammogram within 1 month prior registration protocol therapy need repeat exam Patients must willing provide core tissue biopsy baseline repeat tissue collection 12 cycle protocol therapy White blood cell ( WBC ) &gt; = 3.0 x 109/L Granulocytes ( polymorphs + band ) &gt; = 1.5 x 109/L Platelets &gt; = 100 x 109/L Hemoglobin &gt; = 110 g/L Aspartate aminotransferase ( AST ) = &lt; 1.8 X upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) = &lt; 1.8 X ULN Alkaline phosphatase = &lt; 2 X ULN Serum creatinine = &lt; 115 umol/L ( 1.3mg/dL ) Serum bilirubin = &lt; institution ULN ( except subject Gilbert 's Disease eligible despite elevated serum bilirubin level ) 12 hour fast glucose level &lt; 7.0 mmol/L Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 within 28 day registration Life expectancy &gt; = 5 year Subjects must accessible treatment , adverse event track followup determine treat physician Subject consent authorization release health information must obtain accord local institutional guideline No history malignancy except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease &gt; = 5 year No know diabetes ( type 1 2 ) baseline fast glucose &gt; = 7.0 mmol/L No known hypersensitivity intolerance metformin No condition associate increase risk metforminassociated lactic acidosis ( e.g . congestive heart failure define New York Heart Association [ NYHA ] class III IV functional status , history acidosis type ; habitual intake 3 alcoholic beverage per day ) No current treatment metformin , sulfonylurea , thiazolidinediones insulin reason No breastfeeding No concurrent plan participation randomize trial weight loss exercise intervention trial target insulin , insulinlike growth factor 1 ( IGF1 ) receptor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>